The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Sven Tyge Langkjer; Julia Kenholm; Jeanette Dupont Jensen; Kim Wedervang; Annette Torbøl Brixen; Mie Grunnet; Lars Stenbygaard; Bjørnar Gilje; Hella Danø; Vesna Glavicic; Erik Hugger Jacobsen; Anne Sofie Brems-Eskildsen; Helle Lemvig Kruse; Trine Dongsgaard; Jeppe Neimann; Jürgen Geisler

doi:10.2217/fon-2019-0124

The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Sven Tyge Langkjer, Julia Kenholm, Jeanette Dupont Jensen, Kim Wedervang, Annette Torbøl Brixen, Mie Grunnet, Lars Stenbygaard, Bjørnar Gilje, Hella Danø, Vesna Glavicic, Erik Hugger Jacobsen, Anne Sofie Brems-Eskildsen, Helle Lemvig Kruse, Trine Dongsgaard, Jeppe Neimann, Jürgen Geisler

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

7 Citationer (Scopus)

54 Downloads (Pure)

Abstract

Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

Originalsprog	Engelsk
Tidsskrift	Future Oncology
Vol/bind	15
Udgave nummer	22
Sider (fra-til)	2561-2569
Antal sider	9
ISSN	1479-6694
DOI	https://doi.org/10.2217/fon-2019-0124
Status	Udgivet - aug. 2019

Adgang til dokumentet

10.2217/fon-2019-0124

Langkjer et al. (2019) The NAME trialForlagets udgivne version, 1,45 MBLicens: CC BY-NC-ND 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Langkjer, S. T., Kenholm, J., Jensen, J. D., Wedervang, K., Brixen, A. T., Grunnet, M., Stenbygaard, L., Gilje, B., Danø, H., Glavicic, V., Jacobsen, E. H., Brems-Eskildsen, A. S., Kruse, H. L., Dongsgaard, T., Neimann, J., & Geisler, J. (2019). The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer. Future Oncology, 15(22), 2561-2569. Advance online publication. https://doi.org/10.2217/fon-2019-0124

@article{5123a1876c524339aaec62ed5fadc481,

title = "The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer",

abstract = "Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.",

author = "Langkjer, {Sven Tyge} and Julia Kenholm and Jensen, {Jeanette Dupont} and Kim Wedervang and Brixen, {Annette Torb{\o}l} and Mie Grunnet and Lars Stenbygaard and Bj{\o}rnar Gilje and Hella Dan{\o} and Vesna Glavicic and Jacobsen, {Erik Hugger} and Brems-Eskildsen, {Anne Sofie} and Kruse, {Helle Lemvig} and Trine Dongsgaard and Jeppe Neimann and J{\"u}rgen Geisler",

year = "2019",

month = aug,

doi = "10.2217/fon-2019-0124",

language = "English",

volume = "15",

pages = "2561--2569",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "22",

}

Langkjer, ST, Kenholm, J, Jensen, JD, Wedervang, K, Brixen, AT, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, EH, Brems-Eskildsen, AS, Kruse, HL, Dongsgaard, T, Neimann, J & Geisler, J 2019, 'The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer', Future Oncology, bind 15, nr. 22, s. 2561-2569. https://doi.org/10.2217/fon-2019-0124

TY - JOUR

T1 - The NAME trial

T2 - a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

AU - Langkjer, Sven Tyge

AU - Kenholm, Julia

AU - Jensen, Jeanette Dupont

AU - Wedervang, Kim

AU - Brixen, Annette Torbøl

AU - Grunnet, Mie

AU - Stenbygaard, Lars

AU - Gilje, Bjørnar

AU - Danø, Hella

AU - Glavicic, Vesna

AU - Jacobsen, Erik Hugger

AU - Brems-Eskildsen, Anne Sofie

AU - Kruse, Helle Lemvig

AU - Dongsgaard, Trine

AU - Neimann, Jeppe

AU - Geisler, Jürgen

PY - 2019/8

Y1 - 2019/8

N2 - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

AB - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

U2 - 10.2217/fon-2019-0124

DO - 10.2217/fon-2019-0124

M3 - Journal article

C2 - 31215242

SN - 1479-6694

VL - 15

SP - 2561

EP - 2569

JO - Future Oncology

JF - Future Oncology

IS - 22

ER -

The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Abstract

Adgang til dokumentet

AUB Link

Fingeraftryk

Citationsformater